Solid Organ Transplantation for HIV-Infected Individuals

HIV Medicine (CJ Yoon, Section Editor)
  • 21 Downloads
Part of the following topical collections:
  1. Topical Collection on HIV Medicine

Abstract

Purpose of review

The prevalence of end-stage organ disease is increasing among HIV-infected (HIV+) individuals. Individuals with well-controlled HIV on antiretroviral therapy (ART), without active opportunistic infections or cancer, and with specified minimum CD4 cell counts are appropriate transplant candidates. Infectious disease clinicians can improve access to transplantation for these patients and optimize management pre- and post-transplant.

Recent findings

Clinical trials and registry-based cohort studies demonstrate excellent outcomes for select HIV+ kidney and liver transplant recipients with patient and graft survival similar to HIV-uninfected patients. Elevated allograft rejection rates have been observed in HIV+ individuals; this may be related to a dysregulated immune system, drug interactions, or both. Lymphocyte-depleting immunosuppression has been associated with lower rejection rates without increased infections using national registry data. Hepatitis C virus (HCV) co-infection has been associated with worse outcomes; however, improvements are expected with direct-acting antiviral therapies.

Summary

Solid organ transplantation should be considered for HIV+ individuals with end-stage organ disease. Infectious disease clinicians can optimize ART to avoid pharmacoenhancers, which interact with immunosuppression. The timing of HCV treatment (pre- or post-transplant) should be discussed with the transplant team. Finally, organs from HIV+ donors can now be considered for HIV+ transplant candidates, within research protocols.

Keywords

HIV infection Solid organ transplantation End-stage renal disease End-stage liver disease Kidney transplant Liver transplant Immunosuppression 

Notes

Acknowledgements

The data reported here have been supplied in part by the Minneapolis Medical Research Foundation (MMRF) as the contractor for the Scientific Registry of Transplant Recipients (SRTR). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the SRTR, the Organ Procurement and Transplantation Network (OPTN), or the US Government.

Compliance with ethical standards

Conflict of interest

Ashton A. Shaffer declares that she has no conflict of interest.

Christine M. Durand has received research grants from Bristol Meyers Squibb, Gilead Sciences, Merck Pharmaceuticals, and Viiv Healthcare and has served as a scientific advisor for Bristol Meyers Squibb, Gilead Sciences, and Merck Pharmaceuticals.

Human and animal rights and informed consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. In addition, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. MMWR Morb Mortal Wkly Rep. 2014;63(47):1113–7.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Centers for disease control and prevention. HIV surveillance report. 2016. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 1 Dec 2017.
  3. 3.
    Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853–60.  https://doi.org/10.1056/NEJM199803263381301.CrossRefPubMedGoogle Scholar
  4. 4.
    Singh S, Bradley H, Hu X, Skarbinski J, Hall HI, Lansky A, et al. Men living with diagnosed HIV who have sex with men: progress along the continuum of HIV care—United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(38):829–33.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Losina E, Freedberg KA. Life expectancy in hiv. BMJ. 2011;343(d6015).  https://doi.org/10.1136/bmj.d6015
  6. 6.
    Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: Collaborative analysis of 13 hiv cohort studies. Clin Infect Dis. 2010;50(10):1387–96.CrossRefGoogle Scholar
  7. 7.
    Abbott KC, Trespalacios FC, Agodoa LY, Ahuja TS. Hivan and medication use in chronic dialysis patients in the United States: analysis of the usrds dmms wave 2 study. BMC Nephrol. 2003;4(1):5.  https://doi.org/10.1186/1471-2369-4-5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67(3 Suppl 1):Svii, S1–305.Google Scholar
  9. 9.
    Razzak Chaudhary S, Workeneh BT, Montez-Rath ME, Zolopa AR, Klotman PE, Winkelmayer WC. Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrol Dial Transplant. 2015;30(10):1734–40.  https://doi.org/10.1093/ndt/gfv207.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60(6):941–9.  https://doi.org/10.1093/cid/ciu919.CrossRefPubMedGoogle Scholar
  11. 11.
    Bickel M, Marben W, Betz C, Khaykin P, Stephan C, Gute P, et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med. 2013;14(3):127–35.  https://doi.org/10.1111/j.1468-1293.2012.01045.x.CrossRefPubMedGoogle Scholar
  12. 12.
    Atta MG, Fine DM, Kirk GD, Mehta SH, Moore RD, Lucas GM. Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin Infect Dis. 2007;45(12):1625–32.  https://doi.org/10.1086/523728.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sexton DJ, Reule S, Solid C, Collins AJ, Foley RN. End-stage renal disease from human immunodeficiency virus-associated nephropathy in the United States, 2001 through 2010. JAMA Intern Med. 2014;174(5):809–11.  https://doi.org/10.1001/jamainternmed.2014.29.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis. 2012;59(5):628–35.  https://doi.org/10.1053/j.ajkd.2011.10.050.CrossRefPubMedGoogle Scholar
  15. 15.
    Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61(1):195–202.  https://doi.org/10.1046/j.1523-1755.2002.00094.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2005;40(11):1559–85.  https://doi.org/10.1086/430257.CrossRefPubMedGoogle Scholar
  17. 17.
    Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;59(9):e96–138.  https://doi.org/10.1093/cid/ciu617.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Locke JE, Mehta S, Sawinski D, Gustafson S, Shelton BA, Reed RD, et al. Access to kidney transplantation among HIV-infected waitlist candidates. Clin J Am Soc Nephrol. 2017;12(3):467–75.  https://doi.org/10.2215/CJN.07460716.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sawinski D, Wyatt CM, Casagrande L, Myoung P, Bijan I, Akalin E, et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant. 2009;9(6):1467–71.  https://doi.org/10.1111/j.1600-6143.2009.02637.x.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Trullas JC, Cofan F, Barril G, Martinez-Castelao A, Jofre R, Rivera M, et al. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cart era: a gesida/sen cohort study. J Acquir Immune Defic Syndr. 2011;57(4):276–83.  https://doi.org/10.1097/QAI.0b013e318221fbda.CrossRefPubMedGoogle Scholar
  21. 21.
    Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377(9772):1198–209.  https://doi.org/10.1016/S0140-6736(10)62001-6.CrossRefPubMedGoogle Scholar
  22. 22.
    Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.  https://doi.org/10.1016/S1473-3099(15)00485-5.CrossRefPubMedGoogle Scholar
  23. 23.
    Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192(6):992–1002.  https://doi.org/10.1086/432762.CrossRefPubMedGoogle Scholar
  24. 24.
    Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep. 2013;10(3):226–34.  https://doi.org/10.1007/s11904-013-0169-5.CrossRefPubMedGoogle Scholar
  25. 25.
    Soriano V, Puoti M, Garcia-Gasco P, Rockstroh JK, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22(1):1–13.  https://doi.org/10.1097/QAD.0b013e3282f0e2fd.CrossRefPubMedGoogle Scholar
  26. 26.
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the d:A:D study. Arch Intern Med. 2006;166(15):1632–41.  https://doi.org/10.1001/archinte.166.15.1632.CrossRefPubMedGoogle Scholar
  27. 27.
    Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and Bviruses and alcohol. J Hepatol. 2005;42(6):799–805.  https://doi.org/10.1016/j.jhep.2005.01.022.CrossRefPubMedGoogle Scholar
  28. 28.
    Price JC, Seaberg EC, Latanich R, Budoff MJ, Kingsley LA, Palella FJ Jr, et al. Risk factors for fatty liver in the multicenter aids cohort study. Am J Gastroenterol. 2014;109(5):695–704.  https://doi.org/10.1038/ajg.2014.32.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013;47(2):182–7.  https://doi.org/10.1097/MCG.0b013e318264181d.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):1569–78.  https://doi.org/10.1093/cid/civ101.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Vuille-Lessard E, Lebouche B, Lennox L, Routy JP, Costiniuk CT, Pexos C, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS. 2016;30(17):2635–43.  https://doi.org/10.1097/QAD.0000000000001241.CrossRefPubMedGoogle Scholar
  32. 32.
    Subramanian A, Sulkowski M, Barin B, Stablein D, Curry M, Nissen N, et al. Meld score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology. 2010;138(1):159–64.  https://doi.org/10.1053/j.gastro.2009.09.053.CrossRefPubMedGoogle Scholar
  33. 33.
    Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003;188(10):1412–20.  https://doi.org/10.1086/379254.CrossRefPubMedGoogle Scholar
  34. 34.
    Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005;11(11):1425–30.  https://doi.org/10.1002/lt.20534.CrossRefPubMedGoogle Scholar
  35. 35.
    Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003;76(2):370–5.  https://doi.org/10.1097/01.TP.0000075973.73064.A6.CrossRefPubMedGoogle Scholar
  36. 36.
    Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355–65.  https://doi.org/10.1111/j.1600-6143.2007.02061.x.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–14.  https://doi.org/10.1056/NEJMoa1001197. This prospective observational study showed that select HIV+ individuals with end-stage renal disease were acceptable kidney transplant candidates, with high 1- and 3-year patient and graft survival. It also highlighted concerns for increased allograft rejection in this population.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    •• Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis c and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716–26.  https://doi.org/10.1002/lt.23411. This prospective observational study showed that select HIV+ individuals with end-stage liver disease were acceptable liver transplant candidates, with reasonable 1- and 3-year patient and graft survival. It further demonstrated the increased risk of HIV and hepatitis C virus (HCV) co-infection on acute rejection, graft loss, and post-transplant mortality.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Roland ME, Barin B, Huprikar S, Murphy B, Hanto DW, Blumberg E, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS. 2016;30(3):435–44.  https://doi.org/10.1097/QAD.0000000000000934.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Massie AB, Kucirka LM, Segev DL. Big data in organ transplantation: registries and administrative claims. Am J Transplant. 2014;14(8):1723–30.  https://doi.org/10.1111/ajt.12777.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    • Locke JE, Mehta S, Reed RD, MacLennan P, Massie A, Nellore A, et al. A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol. 2015;26(9):2222–9.  https://doi.org/10.1681/ASN.2014070726. This registry-based study compared post-transplant survival for HIV+ vs. HIV- kidney transplant recipients, finding similar results when restricting to those without hepatitis C virus (HCV) coinfection. HIV+/HCV+ coinfected recipients had worse surival overall, emphasizing the need to treat HCV to improve outcomes in these patients.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    • Locke JE, Durand C, Reed RD, MacLennan PA, Mehta S, Massie A, et al. Long-term outcomes after liver transplantation among human immunodeficiency virus-infected recipients. Transplantation. 2016;100(1):141–6.  https://doi.org/10.1097/TP.0000000000000829.This registry-based study describes 5- and 10-year outcomes for HIV+ liver transplant recipients. Coinfection with hepatitis C virus (HCV) was common (65%), and was associated with an increased risk of death and graft loss. This emphasizes the importance of incorporating HCV treatment to improve post-transplant outcomes for HIV+ recipients.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    • Locke JE, Gustafson S, Mehta S, Reed RD, Shelton B, MacLennan PA, et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg. 2017;265(3):604–8.  https://doi.org/10.1097/SLA.0000000000001761.This registry-based study showed that kidney transplantation conferred improved survival for HIV+ candidates (80% lower risk of death at 5 years) vs. similar HIV+ candidates who remained on dialysis. By demonstrating survival benefit, this study provides evidence that kidney transplantation should be offered to appropriate HIV+ candidates as a superior option compared to dialysis.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    • Locke JE, Reed RD, Mehta SG, Durand C, Mannon RB, MacLennan P, et al. Center-level experience and kidney transplant outcomes in HIV-infected recipients. Am J Transplant. 2015;15(8):2096–104.  https://doi.org/10.1111/ajt.13220.This registry-based study found no association between center-level experience with HIV+ kidney transplant recipients and their post-transplant outcomes. It also showed improvements in outcomes for HIV+ recipients who were transplanted more recently.CrossRefPubMedGoogle Scholar
  45. 45.
    • Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Aguero F, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12(7):1866–76.  https://doi.org/10.1111/j.1600-6143.2012.04028.x. This matched analysis of a prospective observational Spanish study compared 5-year post-liver transplant survival for HIV/hepatitis C virus (HCV) co-infected recipients to those with HCV alone. These findings showed poorer survival for coinfected recipients, but identified a subset of coinfected recipients with similar 5-year survival to HCV+ recipients.CrossRefPubMedGoogle Scholar
  46. 46.
    Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, et al. Virologic and clinical outcomes of hepatitis b virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10(5):1268–75.  https://doi.org/10.1111/j.1600-6143.2010.03070.x.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    • Blumberg EA, Rogers CC, Practice ASTIDCo. Human immunodeficiency virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):169–78.  https://doi.org/10.1111/ajt.12109. This review provides additional commentary on the particular treatment considerations for HIV+ transplant candidates and recipients, including a detailed discussion of antiretroviral treatment regimens, prophylaxis for opportunistic infections, and vaccination strategies for these patients.CrossRefPubMedGoogle Scholar
  48. 48.
    Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177(1):108–13.  https://doi.org/10.1164/rccm.200704-541OC.CrossRefPubMedGoogle Scholar
  49. 49.
    Diaz PT, Clanton TL, Pacht ER. Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med. 1992;116(2):124–8.  https://doi.org/10.7326/0003-4819-116-2-124.CrossRefPubMedGoogle Scholar
  50. 50.
    Bloomfield GS, Leung C. Cardiac disease associated with human immunodeficiency virus infection. Cardiol Clin. 2017;35(1):59–70.  https://doi.org/10.1016/j.ccl.2016.09.003.CrossRefPubMedGoogle Scholar
  51. 51.
    Thao C, Shorr AF, Woods C. Non-infectious pulmonary disorders in HIV. Expert Rev Respir Med. 2017;11(3):209–20.  https://doi.org/10.1080/17476348.2017.1288101.CrossRefPubMedGoogle Scholar
  52. 52.
    Conte AH, Kittleson MM, Dilibero D, Hardy WD, Kobashigawa JA, Esmailian F. Successful orthotopic heart transplantation and immunosuppressive management in 2 human immunodeficiency virus-seropositive patients. Tex Heart Inst J. 2016;43(1):69–74.  https://doi.org/10.14503/THIJ-14-4746.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Calabrese LH, Albrecht M, Young J, McCarthy P, Haug M, Jarcho J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med. 2003;348(23):2323–8.  https://doi.org/10.1056/NEJMoa022935.CrossRefPubMedGoogle Scholar
  54. 54.
    Morgan JA, Bisleri G, Mancini DM. Cardiac transplantation in an HIV-1-infected patient. N Engl J Med. 2003;349(14):1388–9. author reply 1388-1389CrossRefPubMedGoogle Scholar
  55. 55.
    Boignard A, Blanc M, Chavanon O. High-urgency priority heart transplantation in HIV-positive patients on life support: breaking barriers? J Heart Lung Transplant. 2011;30(8):968–9.  https://doi.org/10.1016/j.healun.2011.03.016.PubMedGoogle Scholar
  56. 56.
    Mehdiani A, Petrov G, Akhyari P, Saeed D, Kamiya H, Westenfeld R, et al. Heart transplantation bridged by mechanical circulatory support in a HIV-positive patient. J Card Surg. 2016;31(8):559–61.  https://doi.org/10.1111/jocs.12787.CrossRefPubMedGoogle Scholar
  57. 57.
    Bertani A, Grossi P, Vitulo P, D’Ancona G, Arcadipane A, Nanni Costa A, et al. Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis. Am J Transplant. 2009;9(9):2190–6.  https://doi.org/10.1111/j.1600-6143.2009.02779.x.CrossRefPubMedGoogle Scholar
  58. 58.
    Di Benedetto F, D’Amico G, De Ruvo N, Cocchi S, Montalti R, Cautero N, et al. Combined liver-kidney transplantation in patients infected with human immunodeficiency virus. Transpl Infect Dis. 2011;13(5):501–6.  https://doi.org/10.1111/j.1399-3062.2011.00622.x.CrossRefPubMedGoogle Scholar
  59. 59.
    Toso C, Berney T, Oberholzer J, Chave JP, Martin PY, Zeender E, et al. Kidney-pancreas transplantation in a long-term non-progressor HIV-infected recipient. Am J Transplant. 2003;3(5):631–3.  https://doi.org/10.1034/j.1600-6143.2003.00119.x.CrossRefPubMedGoogle Scholar
  60. 60.
    Grossi PA, Righi E, Gasperina DD, Donati D, Tozzi M, Mangini M, et al. Report of four simultaneous pancreas-kidney transplants in HIV-positive recipients with favorable outcomes. Am J Transplant. 2012;12(4):1039–45.  https://doi.org/10.1111/j.1600-6143.2011.03906.x.CrossRefPubMedGoogle Scholar
  61. 61.
    Dalla Gasperina D, Tozzi M, Astuti N, Balsamo ML, Donati D, Rossi A, et al. Pulmonary tuberculosis in an HIV- and hepatitis C virus-coinfected kidney-pancreas transplant recipient: a case report. Transplant Proc. 2011;43(4):1206–9.  https://doi.org/10.1016/j.transproceed.2011.02.050.CrossRefPubMedGoogle Scholar
  62. 62.
    Akhtar MZ, Patel N, Devaney A, Sinha S, Shankar S, Vaidya A, et al. Simultaneous pancreas kidney transplantation in the HIV-positive patient. Transplant Proc. 2011;43(10):3903–4.  https://doi.org/10.1016/j.transproceed.2011.08.093.CrossRefPubMedGoogle Scholar
  63. 63.
    Miro JM, Ricart MJ, Trullas JC, Cofan F, Cervera C, Brunet M, et al. Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review. Transplant Proc. 2010;42(9):3887–91.  https://doi.org/10.1016/j.transproceed.2010.09.003.CrossRefPubMedGoogle Scholar
  64. 64.
    Hayes K, Van Sickels N, Buell J, Killackey M, Zhang R, Slakey D, et al. Successful transplantation of HIV patients: the Louisiana experience. J La State Med Soc. 2012;164(4):191–3.PubMedGoogle Scholar
  65. 65.
    • Kucirka LM, Durand CM, Bae S, Avery RK, Locke JE, Orandi BJ, et al. Induction immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus. Am J Transplant. 2016;16(8):2368–76.  https://doi.org/10.1111/ajt.13840. This study using claims data showed that HIV+ kidney transplant recipients treated with antithymocyte globulin (ATG) induction therapy had lower rates of acute rejection. ATG was not associated with increased risk of post-transplant infections. These findings provide further support for the use of ATG in induction therapy for HIV+ transplant recipients.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    • Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation. 2014;97(4):446–50.  https://doi.org/10.1097/01.TP.0000436905.54640.8c. This national registry study of 516 HIV+ kidney transplant recipients found no statistically significant increases in graft loss for those receiving antithymocyte globulin (ATG) induction therapy and found a 2.6-fold lower risk of acute rejection, compared to receiving no induction. These findings provide support for the use of ATG in induction therapy for HIV+ transplant recipients.CrossRefPubMedGoogle Scholar
  67. 67.
    Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM. Direct visualization of cross-reactive effector and memory allo-specific cd8 T cells generated in response to viral infections. J Immunol. 2003;170(8):4077–86.  https://doi.org/10.4049/jimmunol.170.8.4077.CrossRefPubMedGoogle Scholar
  68. 68.
    Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med. 2004;10(1):87–92.  https://doi.org/10.1038/nm965.CrossRefPubMedGoogle Scholar
  69. 69.
    Filaci G, Contini P, Brenci S, Lanza L, Scudeletti M, Indiveri F, et al. Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. Tissue Antigens. 1995;46(2):117–23.  https://doi.org/10.1111/j.1399-0039.1995.tb02487.x.CrossRefPubMedGoogle Scholar
  70. 70.
    Canaud G, Dejucq-Rainsford N, Avettand-Fenoel V, Viard JP, Anglicheau D, Bienaime F, et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol. 2014;25(2):407–19.  https://doi.org/10.1681/ASN.2013050564.CrossRefPubMedGoogle Scholar
  71. 71.
    Avettand-Fenoel V, Rouzioux C, Legendre C, Canaud G. HIV infection in the native and allograft kidney: implications for management, diagnosis, and transplantation. Transplantation. 2017;101(9):2003–8.  https://doi.org/10.1097/TP.0000000000001674.CrossRefPubMedGoogle Scholar
  72. 72.
    Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67(6):2440–7.  https://doi.org/10.1111/j.1523-1755.2005.00352.x.CrossRefPubMedGoogle Scholar
  73. 73.
    Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc. 2002;34(5):1540–1.  https://doi.org/10.1016/S0041-1345(02)03011-7.CrossRefPubMedGoogle Scholar
  74. 74.•
    Sawinski D, Shelton BA, Mehta S, Reed RD, MacLennan PA, Gustafson S, Segev DL, Locke JE. Impact of protease inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant. 2017;17(12):3114–22.  https://doi.org/10.1111/ajt.14419. This registry-based study shows the importance of optimizing anti-retroviral therapy to improve post-transplant outcomes for HIV+ individuals. Use of protease-inhibitors in HIV+ kidney transplant recipients was associated with a 1.8-fold higher risk of graft loss and a 1.9-fold risk of death. Avoiding protease-inhibitor-based regimens for HIV+ transplant recipients should be attempted, when feasible.CrossRefPubMedGoogle Scholar
  75. 75.
    van Maarseveen EM, Crommelin HA, Mudrikova T, van den Broek MP, van Zuilen AD. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cart: a pilot study. Transplantation. 2013;95(2):397–402.  https://doi.org/10.1097/TP.0b013e3182734651.CrossRefPubMedGoogle Scholar
  76. 76.
    Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9(8):1946–52.  https://doi.org/10.1111/j.1600-6143.2009.02684.x.CrossRefPubMedGoogle Scholar
  77. 77.
    Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, et al. Cc chemokine receptor 5 and renal-transplant survival. Lancet. 2001;357(9270):1758–61.  https://doi.org/10.1016/S0140-6736(00)04898-4.CrossRefPubMedGoogle Scholar
  78. 78.
    Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–31.  https://doi.org/10.1001/jama.2015.1328.CrossRefPubMedGoogle Scholar
  79. 79.
    Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the astral-5 study. Liver Int. 2017;37(12):1796–804.  https://doi.org/10.1111/liv.13462.CrossRefPubMedGoogle Scholar
  80. 80.
    Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–25.  https://doi.org/10.1056/NEJMoa1503153.CrossRefPubMedGoogle Scholar
  81. 81.
    Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705–13.  https://doi.org/10.1056/NEJMoa1501315.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (mk-5172) and elbasvir (mk-8742) in patients with hepatitis C virus and HIV co-infection (c-edge co-infection): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.  https://doi.org/10.1016/S2352-3018(15)00114-9.CrossRefPubMedGoogle Scholar
  83. 83.
    Brown RS Jr, O’Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22(1):24–33.  https://doi.org/10.1002/lt.24366.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375–82.  https://doi.org/10.1056/NEJMoa1408921.CrossRefPubMedGoogle Scholar
  85. 85.
    Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-target study. Hepatology. 2017;66(4):1090–101.  https://doi.org/10.1002/hep.29258.CrossRefPubMedGoogle Scholar
  86. 86.
    Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166(2):109–17.  https://doi.org/10.7326/M16-1205.CrossRefPubMedGoogle Scholar
  87. 87.
    Bowring MG, Kucirka LM, Massie AB, Luo X, Cameron A, Sulkowski M, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant. 2017;17(2):519–27.  https://doi.org/10.1111/ajt.13976.CrossRefPubMedGoogle Scholar
  88. 88.
    Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis. 2012;60(1):112–20.  https://doi.org/10.1053/j.ajkd.2012.03.015.CrossRefPubMedGoogle Scholar
  89. 89.
    Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10(5):1238–46.  https://doi.org/10.1111/j.1600-6143.2010.03091.x.CrossRefPubMedGoogle Scholar
  90. 90.
    Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362(24):2336–7.  https://doi.org/10.1056/NEJMc0900837.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.••
    Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation—results at 3 to 5 years. N Engl J Med. 2015;372(7):613–20.  https://doi.org/10.1056/NEJMoa1408896. This study of 27 HIV+ kidney transplant recipients of HIV+ donors reports excellent patient and graft survival at 3- (84%) and 5-years (74%) post-transplant and demonstrates the potential for using HIV+ donor organs for HIV+ transplant recipients. US studies investigating HIV+ to HIV+ transplantation are ongoing.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Health R, Services Administration DoH, Human S. Organ procurement and transplantation: implementation of the HIV organ policy equity act. Final rule. Fed Regist. 2015;80(89):26464–7.Google Scholar
  93. 93.
    Boyarsky BJ, Segev DL. From bench to bill: how a transplant nuance became 1 of only 57 laws passed in 2013. Ann Surg. 2016;263(3):430–3.  https://doi.org/10.1097/SLA.0000000000001352.CrossRefPubMedGoogle Scholar
  94. 94.
    Malani P. HIV and transplantation: new reasons for hope. JAMA. 2016;316(2):136–8.  https://doi.org/10.1001/jama.2016.8158.CrossRefPubMedGoogle Scholar
  95. 95.
    Calmy A, van Delden C, Giostra E, Junet C, Rubbia Brandt L, Yerly S, et al. Hiv-positive-to-hiv-positive liver transplantation. Am J Transplant. 2016;16(8):2473–8.  https://doi.org/10.1111/ajt.13824.CrossRefPubMedGoogle Scholar
  96. 96.
    Hathorn E, Smit E, Elsharkawy AM, Bramhall SR, Bufton SA, Allan S, et al. Hiv-positive-to-hiv-positive liver transplantation. N Engl J Med. 2016;375(18):1807–9.  https://doi.org/10.1056/NEJMc1603850.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of EpidemiologyJohns Hopkins School of Public HealthBaltimoreUSA
  3. 3.Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Sidney Kimmel Cancer CenterJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations